The Bilski and Classen decisions can render numerous in vitro diagnostic claims unpatentable.
Michael R. Samardzija, PhD
Advertisement
Michael R. Samardzija, PhD, is counsel at Bracewell & Guiliani LLP
Articles by Michael R. Samardzija, PhD
Advertisement
Latest Updated Articles
Advertisement
Advertisement
Trending on BioPharm International
1
Regeneron's Libtayo Earns CHMP Nod for Expanded EU Dosing
2
Roche, Hansoh Sign Second ADC Pact Covering Preclinical and Roche-Selected Targets
3
The BioPharm Brief: New Approval, Pediatric Progress, and Durable Remission
4
Biomarker Testing Gaps Can Stall Targeted Oncology Therapy, BMS’s Dr Pennell Says
5